כניסה 
עקבו אחרינו בפייסבוק הבדלים בין גרסאות בדף "סרבריקס - Cervarix"
מתוך ויקירפואה
| שורה 8: | שורה 8: | ||
|סל הבריאות=לא כלול | |סל הבריאות=לא כלול | ||
|מסגרת הכללה בסל= | |מסגרת הכללה בסל= | ||
| − | |התוויות=Cervarix is indicated in females from 10 to 45 years of age for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) and cervical intraepithelial neoplasia (CIN), CIN1 and pre-cancerous lesions (CIN 2 and CIN 3) caused by human papillomavirus types 16 and 18. Immunogenicity studies have been conducted in females aged 10 to 14 years and 26 to 45 years to link efficacy in females aged 15 to 25 years to other populations | + | |התוויות=Cervarix is indicated in females from 10 to 45 years of age for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) and [[cervical intraepithelial neoplasia]] (CIN), CIN1 and pre-cancerous lesions (CIN 2 and CIN 3) caused by human papillomavirus types 16 and 18. Immunogenicity studies have been conducted in females aged 10 to 14 years and 26 to 45 years to link efficacy in females aged 15 to 25 years to other populations |
|קיים גם בתכשירים= | |קיים גם בתכשירים= | ||
|שם יצרן=GLAXO SMITH KLINE BIOLOGICALS S.A | |שם יצרן=GLAXO SMITH KLINE BIOLOGICALS S.A | ||
גרסה מ־08:48, 14 בפברואר 2012
| סרבריקס - Cervarix | ||
|---|---|---|
| מרכיב פעיל | HPV-16 L1 ; HPV-18 L1 | |
| קבוצה פרמקולוגית (ATC) | "BACTERIAL AND VIRAL VACCINES, COMBINED" | |
| שם התרופה | "סרבריקס®" (קישור לדף התרופה במאגר משרד הבריאות) |
|
| סל הבריאות | לא כלול | |
התוויות |
Cervarix is indicated in females from 10 to 45 years of age for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US) and cervical intraepithelial neoplasia (CIN), CIN1 and pre-cancerous lesions (CIN 2 and CIN 3) caused by human papillomavirus types 16 and 18. Immunogenicity studies have been conducted in females aged 10 to 14 years and 26 to 45 years to link efficacy in females aged 15 to 25 years to other populations
| |
| שם יצרן | GLAXO SMITH KLINE BIOLOGICALS S.A | |
| שם בעל הרישום | GLAXO SMITH KLINE (ISRAEL) LTD | |
| עלון לרופא | "עלון לרופא באנגלית" | |